

Please add this information to the information that has been sent to committees deliberating on the UCORP report and resolution. It is further evidence that the UCORP position is radically different from the positions being taken by other major health sciences institutions. (Thanks to Joel Moskowitz at Berkeley for sending this information.)

## **HARVARD MEDICAL SCHOOL POLICY ON ACCEPTANCE OF TOBACCO RELATED RESEARCH FUNDING**

The issue of whether or not to accept research funding from entities that derive their funding from tobacco-related sales has been under consideration by many academic and health care institutions, including Harvard Medical School and its affiliated institutions. There are persuasive arguments on both sides of the question. On the one hand, acceptance of such funding without question raises serious public health and public responsibility issues. On the other hand, prohibiting such funding has the potential of depriving researchers and society of a funding source for addressing important non-tobacco related research questions. However, balancing those competing considerations in light of the harm that has been caused by the tobacco industry and its products, and considering HMS's mission as a leader in teaching, research and patient care, the School is instituting a policy to prohibit the acceptance of funding for research or other purposes. This prohibition will apply to funding from companies that make or market tobacco products or from entities supported by such companies such as the Council for Tobacco Research or the Smokeless Tobacco Research Council.

Research Funding Through HMS Effective July 1, 2004, HMS will not submit any new proposals for research to the tobacco related entities described above. Individuals who currently have funding from tobacco related entities will be permitted to apply for non-competing renewal of such research funding but the application must be reviewed and approved prior to submission by the Dean for Basic Sciences and Graduate Studies. Among the criteria to be considered by the Dean in reviewing such a proposal for renewal are the following:

- " the scientific merit of the question to be addressed;
- " the relationship of the scientific aim/purpose of the funding in relation to the funding entity;
- " the existence of any constraints on academic freedom;
- " the use the funder might make of the results (e.g. publicity, marketing);
- " the potential that the funder will use the relationship with HMS as an endorsement.

Research Funding Through Affiliated Institutions Some HMS affiliated institutions have established policies related to the acceptance of tobacco-related funding; others have not. Affiliated institutions are strongly encouraged to consider the issue formally and to promulgate policies that are, at a minimum, consistent with the HMS policy.

<http://www.hms.harvard.edu/spa/policy/tobaccopolicy.pdf>

## **JOHNS HOPKINS SCHOOL OF MEDICINE: TOBACCO COMPANY FUNDING TO CEASE**

The University has made the decision to not accept research funding from any tobacco companies. This decision did not come lightly, despite the fact that it would impact some of our faculty members. It is the right thing to do, as these companies have knowingly caused tremendous morbidity and mortality, which we are working so hard to diminish. For several years, the Bloomberg School of Public Health has had this same policy of not accepting this type of funding. The potential impact of this decision on the School of Medicine was made several years ago, and the analysis showed it would cause insignificant impact. However, in order to not abruptly terminate funding for some investigators, we had approved non-competitive renewals. We have not approved new or competitive renewal applications since that time. This approach allowed investigators to seek alternative funding over the past several years. We have now decided that funding from tobacco companies will no longer be accepted at all.

We hope you will agree that academic freedom in large part allows faculty to explore vast areas via research without limitation, but with public responsibility and moral conviction. Some may argue that our peer institutions have not instituted this policy. However, we continue to have more NIH funding and other funding than most of our peer institutions. Therefore, discontinuation of this type of funding should not affect our rankings among peer institutions. It is our hope that the faculty will support this administrative policy decision.

Chi Dang, MD, PhD

Vice Dean for Research

<http://www.hopkinsmedicine.org/webnotes/editorials/0308.cfm>

## **THE KAROLINSKA INSTITUTE**

June 13th 2002 The Karolinska Institute in Stockholm, which each year awards the Nobel Prize for Medicine, recently decided to cut all links with the tobacco industry so as not to be associated with the damage smoking causes to public health. "It is incredibly important that we who are supposed to work to improve people's health are in no way associated with the tobacco industry," the rector of the Karolinska Institute, Hans Wigzell, said in June 2002.

The Karolinska board decided to cut ties after Wigzell was contacted by a lobbyist from Philip Morris offering research grants.

Agence France Presse, June 13th 2002